参考文献/References:
[1]Cazzola M.Myelodysplastic Syndromes[J].N Engl J Med,2020,383(14):1358-1374.[2]Franke GN,Lückemeier P,Platzbecker U.Allogeneic Stem-Cell ransplantation in Patients With Myelodysplastic Syndromes and Prevention of Relapse[J].Clin Lymphoma Myeloma Leuk,2021,21(1):1-7.[3]赵艳秋,郭芳,杨卫东.地西他滨联合CAG方案治疗高危骨髓增生异常综合征的效果[J].中国实用医刊,2021,48(8):98-101.[4]Lyko F.The DNA methyltransferase family: a versatile toolkit for epigenetic regulation[J].Nat Rev Genet,2018,19(2):81-92.[5]Hoang NM,Rui L.DNA methyltransferases in hematological malignancies[J].J Genet Genomics,2020,47(7):361-372.[6]Duchmann M,Itzykson R.Clinical update on hypomethylating agents[J].Int J Hematol,2019,110(2):161-169.[7]Cetean S,Cainap C,Constantin AM,et al.The importance of the granulocyte-colony stimulating factor in oncology[J].Clujul Med,2015,88(4):468-472.[8]Feng X,Lan H,Ruan Y,et al.Impact on acute myeloid leukemia relapse in granulocyte colony-stimulating factor application: a meta-analysis[J].Hematology,2018,23(9):581-589.[9]郑正,夏徐.不同诱导方案对成人急性髓系白血病的应用效果及安全性研究[J].检验医学与临床,2020,17(1):69-72.[10]Zhao H,Wang C,Yu F,et al.Decitabine combined with CAG regimen in the treatment of elderly patients with acute myeloid leukemia[J].Pak J Med Sci,2020,36(2):141-145.[11]Tang Y,Luo C,Shen S,et al.The efficacy and safety of a homoharringtonine-based protocol for children with acute myeloid leukemia: A retrospective study in China[J].Pediatr Hematol Oncol,2021,38(2):97-107.[12]张文荟,陈香丽,陈玉清,等.高三尖杉酯碱联合阿扎胞苷与Venetoclax治疗难治/复发急性髓系白血病疗效观察[J].新乡医学院学报,2021,38(6):580-584.[13]Yang Y,Li J,Geng Y,et al.Azacitidine regulates DNA methylation of GADD45γ in myelodysplastic syndromes[J].J Clin Lab Anal,2021,35(2):e23597.[14]Papageorgiou SG,Vasilatou D,Kontos CK,et al.Treatment with 5-Azacytidine improves clinical outcome in high-risk MDS patients in the ’real life’ setting: A single center observational study[J].Hematology,2016,21(1):34-41.[15]Palacios-Berraquero ML,Alfonso-Piérola A.Current Therapy of the Patients with MDS: Walking towards Personalized Therapy[J].J Clin Med,2021,10(10):2107.[16]Shapiro RM,Lazo-Langner A.Systematic review of azacitidine regimens in myelodysplastic syndrome and acute myeloid leukemia[J].BMC Hematol,2018(18):3.[17]Ades L,Guerci-Bresler A,Cony-Makhoul P,et al.A phase II study of the efficacy and safety of an intensified schedule of azacytidine in intermediate-2 and high-risk patients with myelodysplastic syndromes: a study by the Groupe Francophone des Myelodysplasies (GFM)[J].Haematologica,2019,104(4):e131-e133.[18]Liu W,Zhou Z,Chen L,et al.Comparison of Azacitidine and Decitabine in Myelodysplastic Syndromes and Acute Myeloid Leukemia: A Network Meta-analysis[J]. Clin Lymphoma Myeloma Leuk,2021,21(6):e530-e544.[19]Agrawal K,Das V,Vyas P,et al.Nucleosidic DNA demethylating epigenetic drugs - A comprehensive review from discovery to clinic[J].Pharmacol Ther,2018(188):45-79.[20]Reenberg PL,Stone RM,Al-Kali A,et al.Myelodysplastic Syndromes, Version 2.2017, NCCN Clinical Practice Guidelines in Oncology[J].J Natl Compr Canc Netw,2017,15(1):60-87.[21]Yang B,Yu R,Cai L,et al.A comparison of therapeutic dosages of decitabine in treating myelodysplastic syndrome: a meta-analysis[J].Ann Hematol,2017,96(11):1811-1823.[22]Joeckel TE,Lubbert M.Clinical results with the DNA hypomethylating agent 5-aza-2’-deoxycytidine (decitabine) in patients with myelodysplastic syndromes: an update[J].Semin Hematol,2012,49(4):330-341.[23]Lee JH,Jang JH,Park J,et al.A prospective multicenter observational study of decitabine treatment in Korean patients with myelodysplastic syndrome[J].Haematologica,2011,96(10):1441-1447.[24]Ren Y,Jiang H,Shi F,et al.Decitabine for myelodysplastic syndromes: dose comparison in a real world clinical setting[J].Leuk Lymphoma,2019,60(7):1731-1739.[25]Steensma DP,Baer MR,Slack JL,et al.Multicenter study of decitabine administered daily for 5 days every 4 weeks to adults with myelodysplastic syndromes: the alternative dosing for outpatient treatment (ADOPT) trial[J].J Clin Oncol,2009,27(23):3842-3848.[26]Wei G,Ni W,Chiao JW,et al.A meta-analysis of CAG (cytarabine,aclarubicin, G-CSF) regimen for the treatment of 1029 patients with acute myeloid leukemia and myelodysplastic syndrome[J].J Hematol Oncol,2011(4):46.[27]Xie M,Jiang Q,Li L,et al.HAG (Homoharringtonine, Cytarabine, G-CSF) Regimen for the Treatment of Acute Myeloid Leukemia and Myelodysplastic Syndrome:A Meta-Analysis with 2,314 Participants[J].PLoS One,2016,11(10):e0164238.[28]姚伟,李静,刘桂玲.阿扎胞苷对中高危骨髓增生异常综合征的临床疗效观察[J].东南大学学报(医学版),2020,39(2):193-196.[29]王共爱,薛克伟,李淑美,等.阿扎胞苷联合CAG方案治疗复发难治急性髓系白血病临床效果分析[J].白血病·淋巴瘤,2020,29(3):157-159.[30]罗秋莲,曲志刚,吴雅君,等.阿扎胞苷联合CAG方案治疗老年急性髓系白血病疗效及对患者血清VEGF和bFGF的影响观察[J].药物流行病学杂志,2021,30(3):170-174.[31]Liu T,Wang J,Li C,et al.Clinical effect of decitabine in the treatment of myelodysplastic syndrome and influencing factors[J].Pak J Med Sci,2020,36(5):1084-1088.[32]高苏,仇惠英,金正明,等.地西他滨单药及联合半程和全程CAG方案治疗骨髓增生异常综合征和急性髓系白血病疗效观察[J].中华血液学杂志,2014,35(11):961-965.[33]杨莹.地西他滨联合HAG方案治疗骨髓增生异常综合征的临床疗效及其安全性评价[J].药物评价研究,2017,40(8):1149-1152.